Disclosed herein is the use of a therapeutically effective substance in the manufacture of a medicament for the treatment of brain cancer, wherein the therapeutically effective substance is (E)-N’-(1-((2S,4S)-4-((4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl)-2-hydroxyethylidene)-6-(2,5-dioxo-2H-pyrrol-1-(5H)yl)hexanehydrazide•HCl (DOXO-EMCH or commonly known as aldoxorubicin or INNO-206)； and wherein the brain cancer is a primary brain cancer selected from the group consisting of glioma, astrocytoma, oligodendroglioma, ependymoma, meningioma, craniopharyngioma, germinoma, pineocytoma, pineoblastoma and glioblastoma multiforme.
